Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea / 대한간학회지
The Korean Journal of Hepatology
; : 25-41, 2009.
Article
en Ko
| WPRIM
| ID: wpr-12965
Biblioteca responsable:
WPRO
ABSTRACT
BACKGROUND/AIMS: The purpose of this study was to evaluate the cost-effectiveness of 1 year and up to 5 years of antiviral treatment for chronic hepatitis B (CHB). METHODS: Two ten-health-state Markov models were developed for CHB patients. The proportion of patients remaining alive in each health state, and healthcare costs and quality-adjusted life years (QALYs) were determined during annual cycles of these Markov models. The total healthcare costs, life years, and QALYs over the 40-year time horizon of the model were calculated. The perspectives of the cost-effectiveness analysis were the Korean healthcare system and the healthcare needs of the CHB patient. RESULTS: Short-course therapy with alpha-interferon or 1-year treatment with pegylated interferon alpha-2a, lamivudine (LMV), or adefovir (ADV) had limited impact on disease progression. In contrast, either LMV-ADV or ADV-LMV as rescue medication administered for 5 years resulted in a more sustained decrease in the rate of disease progression. The cost-effectiveness threshold in Korea was estimated to be approximately 25,000,000 South Korean won. LMV administered for 1 year is cost-effective in comparison with no treatment for both HBeAg-positive and HBeAg-negative CHB patients, but longer duration antiviral therapies administered for up to 5 years in CHB patients were found to be highly cost-effective by international standards. CONCLUSIONS: Antiviral treatment of CHB with LMV or ADV for up to 5 years using the alternative antiviral agent as rescue medication appears to be a cost-effective strategy for both HBeAg-positive and HBeAg-negative CHB patients in Korea. Economic evaluation of antiviral therapies should be studied further and updated, particularly for newer agents.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Antivirales
/
Ácidos Fosforosos
/
Calidad de Vida
/
Índice de Severidad de la Enfermedad
/
Adenina
/
Estudios de Cohortes
/
Modelos Estadísticos
/
Interferón-alfa
/
Análisis Costo-Beneficio
/
Lamivudine
Tipo de estudio:
Etiology_studies
/
Guideline
/
Health_economic_evaluation
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
País/Región como asunto:
Asia
Idioma:
Ko
Revista:
The Korean Journal of Hepatology
Año:
2009
Tipo del documento:
Article